Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

An integrated model of the transcriptome of HER2-positive breast cancer

Tools
- Tools
+ Tools

Kalari, Krishna R., Necela, Brian M., Tang, Xiaojia, Thompson, Kevin J., Lau, Melissa, Eckel-Passow, Jeanette E., Kachergus, Jennifer M., Anderson, S. Keith, Sun, Zhifu, Baheti, Saurabh et al.
(2013) An integrated model of the transcriptome of HER2-positive breast cancer. PLoS One, Volume 8 (Number 11). Article number e79298. doi:10.1371/journal.pone.0079298

[img]
Preview
PDF
WRAP_Rossell_journal.pone.0079298.pdf - Published Version - Requires a PDF viewer.
Available under License Creative Commons Attribution.

Download (3604Kb) | Preview
Official URL: http://dx.doi.org/10.1371/journal.pone.0079298

Request Changes to record.

Abstract

Our goal in these analyses was to use genomic features from a test set of primary breast tumors to build an integrated transcriptome landscape model that makes relevant hypothetical predictions about the biological and/or clinical behavior of HER2-positive breast cancer. We interrogated RNA-Seq data from benign breast lesions, ER+, triple negative, and HER2-positive tumors to identify 685 differentially expressed genes, 102 alternatively spliced genes, and 303 genes that expressed single nucleotide sequence variants (eSNVs) that were associated with the HER2-positive tumors in our survey panel. These features were integrated into a transcriptome landscape model that identified 12 highly interconnected genomic modules, each of which represents a cellular processes pathway that appears to define the genomic architecture of the HER2-positive tumors in our test set. The generality of the model was confirmed by the observation that several key pathways were enriched in HER2-positive TCGA breast tumors. The ability of this model to make relevant predictions about the biology of breast cancer cells was established by the observation that integrin signaling was linked to lapatinib sensitivity in vitro and strongly associated with risk of relapse in the NCCTG N9831 adjuvant trastuzumab clinical trial dataset. Additional modules from the HER2 transcriptome model, including ubiquitin-mediated proteolysis, TGF-beta signaling, RHO-family GTPase signaling, and M-phase progression, were linked to response to lapatinib and paclitaxel in vitro and/or risk of relapse in the N9831 dataset. These data indicate that an integrated transcriptome landscape model derived from a test set of HER2-positive breast tumors has potential for predicting outcome and for identifying novel potential therapeutic strategies for this breast cancer subtype.

Item Type: Journal Article
Subjects: Q Science > QH Natural history > QH426 Genetics
R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Divisions: Faculty of Science, Engineering and Medicine > Science > Statistics
Library of Congress Subject Headings (LCSH): Breast -- Cancer -- Genetic aspects
Journal or Publication Title: PLoS One
Publisher: Public Library of Science
ISSN: 1932-6203
Official Date: 1 November 2013
Dates:
DateEvent
1 November 2013Published
11 January 2013Submitted
20 September 2013Accepted
Volume: Volume 8
Number: Number 11
Number of Pages: 21
Article Number: Article number e79298
DOI: 10.1371/journal.pone.0079298
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Open Access
Funder: 26.2 With Donna Foundation, Eveleigh Family Foundation (EFF), Carmichael Family, Mayo Foundation, National Cancer Institute (U.S.) (NCI)
Grant number: CA129949 (NCI), CA155129 (NCI)

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics

twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us